Advances in Targeted Therapy for R/R CLL

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.

EP. 1: Chronic Lymphocytic Leukemia Treatment Landscape

January 28th 2022

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.

EP. 2: Covalent BTK Inhibitors and Common Challenges

January 28th 2022

Dr Lamanna introduces covalent BTK inhibitors and their use in patients with CLL

EP. 3: Challenges With BTK Inhibitors

February 4th 2022

Dr Lamanna explains the challenges associated with BTK inhibitors.

EP. 4: Challenges Continued

February 4th 2022

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.

EP. 5: Non-Covalent BTK Inhibitors

February 11th 2022

Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.

EP. 6: Clinical Implications of BTK Inhibitors in CLL

February 11th 2022

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

EP. 7: Clinical Implications Continued

February 18th 2022

Dr Lamanna expands on BTK clinical implications within CLL therapy.

EP. 8: BTK Inhibitors and Other B-Cell Malignancies

February 18th 2022

Two experts discuss the use of BTK inhibitors in the treatment of other B-cell malignancies.

EP. 9: Future Directions for BTK Inhibitors

February 18th 2022

Nicole Lamanna, MD, and Nirav N. Shah, MD, conclude with their thoughts on the future of BTK inhibitors in CLL.